NeurologyLive Friday 5 — June 18, 2021

Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Impact of the Approval of Aducanumab on the Treatment Landscape in Alzheimer Disease

Alzheimer disease experts Richard S. Isaacson, MD, and Marc E. Agronin, MD, discuss the impact of the approval of aducanumab on the treatment landscape and other drugs in development for the treatment of Alzheimer disease.

2: MRI in Multiple Sclerosis Guidelines Update: North America, Europe Align on New Recommendations

These consensus guidelines are significant not only for their key updates to clinical practice but for their representation of a more unified, global approach to diagnosing and monitoring patients with multiple sclerosis. They were developed by the MAGNIMS, CMSC, and NAIMS groups.

3: NeuroVoices: Michael J. Thorpy, MD, on FT218, State of Current Sleep Care

The director of the Sleep-Wake Disorders Center at Montefiore Medical Center detailed the overall state of sleep care and the advantages the investigational narcolepsy drug FT218 brings to the growing pipeline of therapies and other topics from SLEEP 2021.

4: Peer Exchange: Managing Patient/Parent Expectations in Dravet

Joseph Sullivan, MD; Trevor J. Resnick, MD; Elizabeth A. Thiele MD, PhD; and Elaine C. Wirrell, MD, engage in a discussion on having conversations with the parents of patients with Dravet syndrome with regards to adjustments to therapy and managing their expectations.

5: Holding On to Hope in Huntington Disease

Daniel O. Claassen, MD, MS, details that despite a few surprising program failures early this year from Roche and Wave Life Sciences, there is plenty of potential worth holding on to in the Huntington disease pipeline.

If you missed your chance to see the June broadcast of our free webinar series, "The Ever-Changing Face of Multiple Sclerosis," put on in partnership with the Consortium of Multiple Sclerosis Centers, don't fret! You can join Ahmed Obeidat, MD, PhD; Anne Cross, MD; and Gloria von Geldern, MD, and others as they discuss the evolution of therapeutics for the treatment of multiple sclerosis.

To view the enduring version of either of the first 3 programs, click here for our Future Leaders in Neurology section.